Modality
Radioligand
MOA
BETi
Target
TIGIT
Pathway
NF-κB
SLEUC
Development Pipeline
Preclinical
Nov 2024
→ Aug 2030
PreclinicalCurrent
NCT05947467
337 pts·SLE
2025-12→2030-08·Not yet recruiting
NCT08638692
169 pts·UC
2024-11→TBD·Terminated
506 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-054.3y awayInterim· SLE
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2030-08-05 · 4.3y away
SLE
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05947467 | Preclinical | SLE | Not yet recr... | 337 | Biomarker |
| NCT08638692 | Preclinical | UC | Terminated | 169 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |